Puma Biotechnology, Inc. (PBYI)
PBYINASDAQ-GSBiotechnology: Pharmaceutical Preparations
$8.40
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $433.35m
- P/E
- 18.3
- EPS, last 4 quarters
- $0.4600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.58 to $11.50
- Average volume
- 369.4k
- Previous close
- $8.40
Earnings
next estimate $0.2300Next report
Dec 2025
+36.8%
Mar 2026
+58.8%
Jun 2026
+166.7%
Sep 2026
+83.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $54.48m | $75.45m | $44.81m | $56.50m |
| Gross profit | $42.30m | $52.33m | $34.39m | $44.03m |
| Operating income | $9.57m | $17.11m | -$3.83m | $7.58m |
| Net income | $8.84m | $13.44m | -$3.75m | $8.19m |
Last four quarters: revenue $231.24m, margin 11.6%, free cash flow –
News
8 latest- Puma: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 2 days ago
- Puma Biotechnology (PBYI) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- Puma Biotechnology Q3 Earnings Call HighlightsMarketBeat · 4 days ago
- Puma Biotech (PBYI) Tops Q3 Earnings EstimatesZacks · 5 days ago
- Adma Biologics (ADMA) Q3 Earnings and Revenues Beat EstimatesZacks · 6 days ago
- Puma Biotechnology Consensus Price Target Raised 20.00% to $6.12Fintel · Nov 2, 2026
- Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?Zacks · Oct 20, 2026
- The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyZacks · Oct 19, 2026
The company
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- pumabiotechnology.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.